Join the Oncology Voice Network. Join for Free
Full Outsourcing Leads to Loss of Control.

Full Outsourcing Leads to Loss of Control.


Share This Article


Summary

When organizations outsource everything, they lose the institutional knowledge and strategic control needed to make critical development decisions.

Full Outsourcing Leads to Loss of Control.

One Idea Worth Acting On.

A biotech hands an entire pivotal oncology trial to a major CRO to maximize efficiency and reduce overhead.

One year later: enrollment is stalled, timelines are slipping, budgets have exploded, and data quality concerns now threaten the regulatory filing.

The sponsor blames the vendor.

The real failure was never the CRO's execution. It was the sponsor's abdication of accountability.

What's Actually Happening

When internal teams are stretched, full outsourcing feels like a solution. The CRO manages the sites, runs the trial, delivers the data, and hands back a regulatory package. The sponsor gets the output without the operational burden.

Except oncology trials are not assembly lines. They are dynamic, high-stakes scientific systems that require constant judgment, adaptation, and oversight.

Unexpected safety signals emerge. Enrollment patterns shift. Protocol deviations accumulate. Operational decisions rapidly affect scientific integrity. When the sponsor has disengaged from those realities, minor problems compound into systemic failures — and by the time leadership recognizes the damage, timelines and budgets are already deeply compromised.

The problem is not outsourcing. It is the assumption that outsourcing the execution also outsources the accountability. It does not. The CRO does not own the molecule. It does not carry the scientific, regulatory, financial, or reputational risk the sponsor carries. It cannot make the judgment calls that only the sponsor can make.

Why This Matters

When organizations fully outsource their pipeline execution, they slowly surrender institutional knowledge about their own asset. The team that should be building deep expertise in the molecule's behavior across patient populations is instead reviewing reports from a vendor who is managing fifteen other programs simultaneously.

That knowledge gap does not close after the trial ends. It follows the asset into the regulatory filing, the launch, and the post-approval lifecycle — at every stage where the organization needs to defend decisions it was not present to make.

Where It Breaks in the Real World

A lean biotech outsources a Phase 3 program and reduces direct oversight to monthly steering committee calls. Enrollment starts slowly at key sites. The CRO flags it as a site performance issue and activates backup sites.

Six months later the backup sites have introduced a patient population that differs meaningfully from the primary sites — different prior treatment history, different performance status distribution. The difference is not large enough to fail the trial. It is large enough to complicate the subgroup analysis the payer dossier depends on.

The sponsor did not make that decision. The sponsor did not know that decision was being made. Full outsourcing created the condition for it. As Dr. Roy Baynes, veteran Clinical Development leader and contributor to Voices of Oncology, describes it: programmatically outsourced trials historically produce severe cost overruns, major delays, and critical quality failures. Not because CROs are incapable. Because once the sponsor disconnects from operational reality, strategic alignment begins to weaken, communication fragments, and scientific nuance gets diluted.

What Needs to Change

Outsourcing operational execution is legitimate and often necessary. Outsourcing scientific accountability is not.

The sponsor needs named internal ownership of every major trial decision — not as oversight bureaucracy but as genuine scientific stewardship. Someone inside the organization who understands the molecule, knows the patients, and has the authority to redirect the CRO when the trial requires it.

The organizations that run the most successful outsourced programs are not the ones that hand off and step back. They are the ones that stay close to the science while delegating the operations.

The Bottom Line

A CRO can run your trial. It cannot own your molecule.

The moment a sponsor forgets that distinction is the moment the trial starts running without the judgment it needs.

Add Your Voice — Where are you seeing this? What's working — and what's not?

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN